Browsing by Author "Aslan G."
Now showing 1 - 14 of 14
Results Per Page
Sort Options
Item Vitamin D receptor gene polymorphism in children with urinary tract infection(2012) Aslan S.; Akil I.; Aslan G.; Onay H.; Ozyurt B.C.; Ozkinay F.It is known that small alterations leading to different vitamin D receptor (VDR) alleles affect resistance or susceptibility to infections. In this study, we examined VDR gene polymorphisms in urinary tract infections (UTI), which are common and an important cause of morbidity in children and subsequently of renal scar formation. We evaluated 92 patients diagnosed with UTI and 105 children without prior history of UTI as a control group. The VDR gene polymorphisms BsmI, FokI, ApaI, and TaqI were evaluated in patients and controls. BsmI polymorphism genotype distribution was similar between groups. There was a significant difference between groups for FokI (p=0<001); for the ff genotype, the risk of UTI was significantly increased (p<0.01) ,at 3.94 times higher (odds ratio=3.94; 95% confidence interval 1.71-9.09). ApaI polymorphism was significantly increased in the control group (p<0.01) and evaluated as a protective factor. Comparing the TaqI genotype between groups, there was no statistically significant difference, but in both Tt and tt genotypes, there was minimal increased risk of UTI. The results of this study suggest that VDR gene polymorphisms can be important for susceptibility to UTI and renal scar formation. Association between VDR polymorphisms and UTI is in accordance with the understanding of how vitamin D modulates the immune response against infections. © IPNA 2011.Item Public awareness of testicular cancer and self-examination in Turkey: A multicenter study of Turkish Urooncology Society(2013) Kuzgunbay B.; Yaycioglu O.; Soyupak B.; Kayis A.A.; Ayan S.; Yavascaoglu I.; Cal C.; Beduk Y.; Aslan G.; Mungan A.; Kaplan M.; Muezzinoglu T.; Bozlu M.; Turkeri L.Background: Testicular self-examination is the easiest and cheapest way to scan testicular cancer. However, the public awareness about testicular self-examination is very low. We aimed to investigate the public awareness of Turkish people about testicular cancer and testicular self-examination. Methods: We performed a survey consisting of 10 questions concerning testicular cancer and testicular self-examination in 799 students in the first year of 12 different medical schools. Aiming for a common method of data collection, the questionnaires were administered to the students during a class just before the lesson started. The whole data from all of the centers were pooled in a common data-base file. Results: Eighty-nine (11.1%) of the participants reported that they had knowledge about testicular cancer, but only 11 (1.4%) of them answered all the questions about testicular cancer correctly. Eight (1%) of the participants reported that they had been performing testicular self-examination routinely once a month. Four (0.5%) of them were both well informed about testicular cancer and had been performing testicular self-examination once a month as suggested. Conclusion: The present study showed that awareness on testicular cancer and testicular self-examination is very low and suggests a need for efforts in Turkey to increase public awareness and education. © 2013 Elsevier Inc.Item The course of spinal tuberculosis (Pott disease): Results of the multinational, multicentre Backbone-2 study(Elsevier B.V., 2015) Batirel A.; Erdem H.; Sengoz G.; Pehlivanoglu F.; Ramosaco E.; Gülsün S.; Tekin R.; Mete B.; Balkan I.I.; Sevgi D.Y.; Giannitsioti E.; Fragou A.; Kaya S.; Cetin B.; Oktenoglu T.; Celik A.D.; Karaca B.; Horasan E.S.; Ulug M.; Senbayrak S.; Kaya S.; Arslanalp E.; Hasbun R.; Ates-Guler S.; Willke A.; Senol S.; Inan D.; Güclü E.; Ertem G.T.; Koc M.M.; Tasbakan M.; Ocal G.; Kocagoz S.; Kusoglu H.; Güven T.; Baran A.I.; Dede B.; Karadag F.Y.; Yilmaz H.; Aslan G.; Al-Gallad D.A.; Cesur S.; El-Sokkary R.; Sirmatel F.; Savasci U.; Karaahmetoglu G.; Vahaboglu H.We aimed to describe clinical, laboratory, diagnostic and therapeutic features of spinal tuberculosis (ST), also known as Pott disease. A total of 314 patients with ST from 35 centres in Turkey, Egypt, Albania and Greece were included. Median duration from initial symptoms to the time of diagnosis was 78 days. The most common complications presented before diagnosis were abscesses (69%), neurologic deficits (40%), spinal instability (21%) and spinal deformity (16%). Lumbar (56%), thoracic (49%) and thoracolumbar (13%) vertebrae were the most commonly involved sites of infection. Although 51% of the patients had multiple levels of vertebral involvement, 8% had noncontiguous involvement of multiple vertebral bodies. The causative agent was identified in 41% of cases. Histopathologic examination was performed in 200 patients (64%), and 74% were consistent with tuberculosis. Medical treatment alone was implemented in 103 patients (33%), while 211 patients (67%) underwent diagnostic and/or therapeutic surgical intervention. Ten percent of the patients required more than one surgical intervention. Mortality occurred in 7 patients (2%), and 77 (25%) developed sequelae. The distribution of the posttreatment sequelae were as follows: 11% kyphosis, 6% Gibbus deformity, 5% scoliosis, 5% paraparesis, 5% paraplegia and 4% loss of sensation. Older age, presence of neurologic deficit and spinal deformity were predictors of unfavourable outcome. ST results in significant morbidity as a result of its insidious course and delayed diagnosis because of diagnostic and therapeutic challenges. ST should be considered in the differential diagnosis of patients with vertebral osteomyelitis, especially in tuberculosis-endemic regions. Early establishment of definitive aetiologic diagnosis and appropriate treatment are of paramount importance to prevent development of sequelae. © 2015 European Society of Clinical Microbiology and Infectious Diseases.Item Comparison of brucellar and tuberculous spondylodiscitis patients: Results of the multicenter "backbone-1 Study"(Elsevier Inc., 2015) Erdem H.; Elaldi N.; Batirel A.; Aliyu S.; Sengoz G.; Pehlivanoglu F.; Ramosaco E.; Gulsun S.; Tekin R.; Mete B.; Balkan I.I.; Sevgi D.Y.; Giannitsioti E.; Fragou A.; Kaya S.; Cetin B.; Oktenoglu T.; Dogancelik A.; Karaca B.; Horasan E.S.; Ulug M.; Inan A.; Kaya S.; Arslanalp E.; Ates-Guler S.; Willke A.; Senol S.; Inan D.; Guclu E.; Tuncer-Ertem G.; Meric-Koc M.; Tasbakan M.; Senbayrak S.; Cicek-Senturk G.; Sirmatel F.; Ocal G.; Kocagoz S.; Kusoglu H.; Guven T.; Baran A.I.; Dede B.; Yilmaz-Karadag F.; Kose S.; Yilmaz H.; Aslan G.; Algallad D.A.; Cesur S.; El-Sokkary R.; Bekiroǧlu N.; Vahaboglu H.Background Context No direct comparison between brucellar spondylodiscitis (BSD) and tuberculous spondylodiscitis (TSD) exists in the literature. Purpose This study aimed to compare directly the clinical features, laboratory and radiological aspects, treatment, and outcome data of patients diagnosed as BSD and TSD. Study Design A retrospective, multinational, and multicenter study was used. Patient Sample A total of 641 (TSD, 314 and BSD, 327) spondylodiscitis patients from 35 different centers in four countries (Turkey, Egypt, Albania, and Greece) were included. Outcome Measures The pre- and peri- or post-treatment spinal deformity and neurologic deficit parameters, and mortality were carried out. Methods Brucellar spondylodiscitis and TSD groups were compared for demographics, clinical, laboratory, radiological, surgical interventions, treatment, and outcome data. The Student t test and Mann-Whitney U test were used for group comparisons. Significance was analyzed as two sided and inferred at 0.05 levels. Results The median baseline laboratory parameters including white blood cell count, C-reactive protein, and erythrocyte sedimentation rate were higher in TSD than BSD (p<.0001). Prevertebral, paravertebral, epidural, and psoas abscess formations along with loss of vertebral corpus height and calcification were significantly more frequent in TSD compared with BSD (p<.01). Surgical interventions and percutaneous sampling or abscess drainage were applied more frequently in TSD (p<.0001). Spinal complications including gibbus deformity, kyphosis, and scoliosis, and the number of spinal neurologic deficits, including loss of sensation, motor weakness, and paralysis were significantly higher in the TSD group (p<.05). Mortality rate was 2.22% (7 patients) in TSD, and it was 0.61% (2 patients) in the BSD group (p=.1). Conclusions The results of this study show that TSD is a more suppurative disease with abscess formation requiring surgical intervention and characterized with spinal complications. We propose that using a constellation of constitutional symptoms (fever, back pain, and weight loss), pulmonary involvement, high inflammatory markers, and radiological findings will help to differentiate between TSD and BSD at an early stage before microbiological results are available. © 2015 Elsevier Inc.Item Multicenter evaluation of crystal violet decolorization assay (CVDA) for rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis(Nature Publishing Group, 2016) Coban A.Y.; Akbal A.U.; Bicmen C.; Albay A.; Sig A.K.; Uzun M.; Selale D.S.; Ozkutuk N.; Surucuoglu S.; Albayrak N.; Ucarman N.; Ozkutuk A.; Esen N.; Ceyhan I.; Ozyurt M.; Bektore B.; Aslan G.; Delialioğlu N.; Alp A.The aim of this multicenter study was to evaluate the performance of the crystal violet decolorization assay (CVDA) for detection of multidrug resistant tuberculosis (MDR-TB). This study was performed in 11 centers in two phases. A total of 156 isolates were tested for INH and RIF resistance. In the phase I, 106 clinical isolates were tested in the Center 1–7. In the phase 2, 156 clinical isolates were tested in the center 1–6, center 8–11. Eighty six of 156 tested isolates were the same in phase I. Agreements were 96.2–96.8% for INH and 98.1–98.7% for RIF in the phase I-II, respectively. Mean time to obtain the results in the phase I was 14.3 ± 5.4 days. In the phase II, mean time to obtain the results was 11.6 ± 3.5 days. Test results were obtained within 14days for 62.3% (66/106) of isolates in the phase I and 81.4% (127/156) of isolates in the phase II. In conclusion, CVDA is rapid, reliable, inexpensive, and easy to perform for rapid detection of MDR-TB isolates. In addition, it could be adapted for drug susceptibility testing with all drugs both in developed and developing countries. © 2016, The Author(s).Item A new colorimetric method for rapid detection of ethambutol and streptomycin resistance in Mycobacterium tuberculosis: crystal violet decolorization assay (CVDA)(Springer Netherlands, 2019) Coban A.Y.; Akbal A.U.; Ceyhan I.; Uzun M.; Sertel Selale D.; Aslan G.; Delialioglu N.; Ozyurt M.; Bektore B.; Bicmen C.; Aslanturk A.; Ucarman N.; Albay A.; Sig A.K.; Ozkutuk N.; Surucuoglu S.Streptomycin (STR) and ethambutol (EMB) are important drugs used for the treatment of tuberculosis. There is a need for fast, reliable and inexpensive methods for detecting resistance to these drugs. The aim of this study was to evaluate the performance of the crystal violet decolorization assay (CVDA) for the detection of STR and EMB resistance that is important drugs in tuberculosis treatment. In this study, drug susceptibility testing was performed on 140 Mycobacterium tuberculosis isolates provided from nine centers. Three tubes were used for each isolate. One of the tubes had a concentration of 2 mg/L STR and the other 5 mg/L EMB. The third was drug-free control tube. Sensitivity, specificity, positive predictive value (PPD), negative predictive value (NPD) and agreement for STR were found to be 81.8%, 94.6%, 87.8%, 91.5% and 90.57%, respectively. For EMB, sensitivity, specificity, PPD, NPD, and agreement were found to be 76%, 98.23%, 90.47%, 94.87% and 94.2%, respectively. The results were obtained in 11.3 ± 2.7 days (8–21 days). CVDA is rapid, reliable, inexpensive, and easy to perform for rapid detection of STR and EMB resistance, and it could be adapted for drug susceptibility testing. © 2018, Springer Nature Switzerland AG.Item How accurate is radiological imaging for perirenal fat and renal vein invasion in renal cell carcinoma?(John Wiley and Sons Inc, 2021) Ucer O.; Muezzinoglu T.; Ozden E.; Aslan G.; Izol V.; Bayazit Y.; Altan M.; Akdogan B.; Ozen H.; Sozen S.; Cetin S.; Suer E.; Esen B.; Baltaci S.Objective: To evaluate the accuracy of radiological staging, especially renal venous and perirenal fat invasion, in renal cell carcinoma (RCC). Material and Methods: Data of 4823 renal tumour patients from Renal Tumor Database of Association of Uro-oncology in Turkey were evaluated. Of 4823 patients, 3309 RCC patients had complete radiological, and histopathological data were included to this study. The Pearson chi-squared test (χ2) was used to compare radiological and histopathological stages. Results: The mean (SD) age of 3309 patients was 58 (12.3). Preoperative radiological imaging was performed using computed tomography (CT) (n = 2510, 75.8%) or magnetic resonance imaging (MRI) (n = 799, 24.2%). There was a substantial concordance between radiological and pathological staging (к = 0.52, P <.001). Sensitivities of radiological staging in stages I, II, III and IV were 90.7%, 67.3%, 27.7% and 64.2%, respectively. The sensitivity in stage III was lower than the other stages. Subanalysis of stage IIIa cases revealed that, for perirenal fat invasion and renal vein invasion, sensitivity values were 15.4% and 11.3%, respectively. Conclusions: There was a substantial concordance between radiological (CT and/or MRI) and pathological T staging in RCC. However, this is not true for T3 cases. Sensitivity of preoperative radiological imaging in patients with pT3a tumours is insufficient and lower than the other stages. Consequently, preoperative imaging in patients with T3 RCC has to be improved, in order to better inform the patients regarding prognosis of their disease. © 2021 John Wiley & Sons LtdItem Multicenter evaluation of AYC.2.2 agar for the isolation of mycobacteria from clinical samples(Indian Association of Medical Microbiologists, 2022) Coban A.Y.; Ceyhan I.; Uzun M.; Erkose Genc G.; Bicmen C.; Ozkutuk N.; Surucuoglu S.; Yanar O.; Aslan G.; Kurnaz N.; Tanriverdi Cayci Y.Purpose: The aim of this multicenter study is to evaluate AYC.2.2 agar for the isolation of mycobacteria from clinical samples. Methods: Totally 5559 media were tested in 7 centers. AYC.2.2 agar media for the study were prepared by C1 and sent to other centers under appropriate conditions. Other media except AYC.2.2 agar were purchased commercially. The media were subjected to routine laboratory operations in the center where they were sent. After the samples received for routine processing (in all centers, samples were processed with the same method (NALC-NaOH)), they were cultivated on routine media and AYC.2.2 agar afterward. Results: C1: Average growth time was determined as 12.74±3.74 days with MGIT 960 system; 24.42±4.75 days with LJ and 24.37±4.96 days with AYC.2.2 agar. C2: Average growth time was determined as 18.25±9.32 days with TK-Medium, 28.73±7.44 days with LJ, and 31.72±6.35 days with AYC.2.2 agar. C3: Average growth time was determined as 20.48±7.24 days with Ogawa medium, 20.74±7.12 days with LJ, and 20.26±7.43 days with AYC.2.2 agar. C4: Average growth time was determined as 15.27±6.37 days with MGIT 960 system, 22.14±9.1 days with LJ, and 22±8.45 days with AYC.2.2 agar. C5: Average growth time was determined as 13±4.24 days with MGIT 960 system, 32.16±6.23 days with LJ, and 33±5.73 days with AYC.2.2 agar. C6: Average growth time was determined as 9±3.11 days with MGIT 960 system, 18.68±5.32 days with LJ, and 18.34±4.63 days AYC.2.2 agar. C7: Average growth time was determined as 14.74±7.65 with MGIT 960 system, 26.01±8.21 days with LJ, and 26.24±7.88 days with AYC.2.2 agar. Conclusions: In conclusion, similar results were obtained with LJ and Ogawa media and AYC.2.2 agar. Furthermore, more studies should be conducted for isolation of M. tuberculosis and performing antibiotic susceptibility tests using AYC.2.2 agar before it can be used as a routine media in the laboratories. © 2022 Indian Association of Medical MicrobiologistsItem Sextant Biopsy-Based Criteria for Clinically Insignificant Prostate Cancer Are Also Valid for the 12-Core Prostate Biopsy Scheme: A Multicenter Study of Urooncology Association, Turkey(S. Karger AG, 2022) Çelik S.; Klzllay F.; Yörükoǧlu K.; Aslan G.; Ozen H.; Akdogan B.; Sozen S.; Baltaci S.; Muezzinoglu T.; Izol V.; Bayazlt Y.; Narter F.; Türkeri L.Background: Epstein criteria based on sextant biopsy are assumed to be valid for 12-core biopsies. However, very scarce information is present in the current literature to support this view. Objectives: To investigate the validity of Epstein criteria for clinically insignificant prostate cancer (PCa) in a cohort of the currently utilized 12-core prostate biopsy (TRUS-Bx) scheme in patients with low-risk and intermediate-risk PCa. Method: Pathological findings were separately evaluated in the areas matching the sextant biopsy (6-core paramedian) scheme and in all 12-core schemes. Patients were divided into 2 groups according to the final pathology report of RP as true clinically significant PCa (sPCa) and insignificant PCa (insPCa) groups. Predictive factors (including Epstein criteria) and cutoff values for the presence of insPCa were separately evaluated for 6- and 12-core TRUS-Bx schemes. Then, different predictive models based on Epstein criteria with or without additional biopsy findings were created. Results: A total of 442 patients were evaluated. PSA density, biopsy GS, percentage of tumor and number of positive cores, PNI, and HG-PIN were independent predictive factors for insPCa in both TRUS-Bx schemes. For the 12-core scheme, the best cutoff values of tumor percentage and number of positive cores were found to be ≤50% (OR: 3.662) and 1.5 cores (OR: 2.194), respectively. The best predictive model was found to be that which added 3 additional factors (PNI and HG-PIN absence and number of positive cores) to Epstein criteria (OR: 6.041). Conclusions: Using a cutoff value of "1"for the number of positive biopsy cores and absence of biopsy PNI and HG-PIN findings can be more useful for improving the prediction model of the Epstein criteria in the 12-core biopsy scheme. © 2021 Authors.Item Effect of pelvic lymph node dissection and its extent on oncological outcomes in intermediate-risk prostate cancer patients: A multicenter study of the Turkish Uro-oncology Association(John Wiley and Sons Inc, 2022) Izol V.; Ok F.; Aslan G.; Akdogan B.; Sozen S.; Ozden E.; Celik O.; Muezzinoglu T.; Turkeri L.; Akdogan N.; Baltaci S.Background: Pelvic lymph node dissection (PLND) is the gold standard method for lymph node staging in prostate cancer. We aimed to evaluate the effect of PLND combined with radical prostatectomy (RP) on oncological outcomes in D'Amico intermediate-risk prostate cancer (IRPC) patients. Methods: Patients with D'Amico IRPC were included in the study. In the overall cohort and subgroups (biopsy International Society of Urological Pathology [ISUP] grade group 2 and 3), patients were divided into two groups as PLND and no-PLND. More extensive PLND, defined as a number of removed nodes (NRN) ≥ 75th percentile. Results: After exclusion, a total of 631 patients were included: 351 (55.6%) had PLND and 280 (44.4%) had no-PLND. The mean age was 63.1 ± 3.60 years. The median NRN was 8.0 (1.0–40.0). The mean follow-up period was 47.7 ± 37.5 months. The lymph node involvement (LNI) rate was 5.7% in the overall cohort, 3.9% in ISUP grade 2, and 10.8% in ISUP grade 3. Patients with PLND were associated with more aggressive clinicopathologic characteristics but no significant difference in biochemical recurrence-free survival (BCRFS) was found between patients with PLND and no-PLND (p = 0.642). In the subgroup analysis for ISUP grades 2 and 3, no significant difference in BCRFS outcomes was found in patients with PLND and No-PLND (p = 0.680 and p = 0.922). Also, PLND extent had no effect on BCRFS (p = 0.569). The multivariable Cox regression model adjusted for preoperative tumor characteristics revealed that prostate specific antigen (PSA) (HR: 1.18, 95% CI: 1.01–1.25; p = 0.048) was an independent predictor of biochemical recurrence (BCR). The optimum cut-off value for PSA, which can predict BCRFS, was assigned to be 7.81 ng/ml, with an AUC of 0.63 (95% CI: 0.571–0.688). The highest sensitivity and specificity were 0.667 and 0.549. Conclusion: Overall and cancer-specific survival analyzes were not evaluated because not enough events were observed. Neither PLND nor its extent improved BCRFS outcomes in IRPC. The LNI rate is low in patients with biopsy ISUP grade 2 and the BCR rate is low in those with PSA < 7.81 ng/dl so PLND can be omitted in these IRPC patients. © 2022 Wiley Periodicals LLC.Item Adjuvant Treatment Approaches after Radical Prostatectomy with Lymph Node Involvement(Asian Pacific Organization for Cancer Prevention, 2022) Tavukçu H.H.; Erbatu O.; Akdoğan B.; İzol V.; Yücetaş U.; Sözen S.; Aslan G.; Şahin B.; Tinay İ.; Müezzinoğlu T.; SumerObjective: The aim of this study was to evaluate the adjuvant treatment preferences and effects on disease progression in patients with pathologically positive lymph node prostate cancer. Methods: Patients who underwent radical prostatectomy from the prostate cancer database of the Turkish Urooncology Association with lymph node involvement were included in the study. Database includes prostate cancer patients from many experience Urooncology centers of Turkey. Adjuvant treatment approaches and the factors that effect the PSA recurrrence was analysed. Results: Postoperative median 2 (1-3) lymph nodes were found to be positive, and the median lymph node density was reported as 0.13 (0.07-0.25). Seventy-four percent of patients received adjuvant treatment postoperatively. Seventy four of the patients (46.54%) received hormonal therapy in combination with radiotherapy; 47 of them (29.55%) received only hormonal treatment and 20(12.57%) only received radiotherapy. The number of lymph nodes removed was less in the group requiring adjuvant treatment, and this group had a higher rate of surgical margin positivity and seminal vesicle invasion. In addition, adjuvant treatment group had a statistically significant higher lymph node density. There was no significant difference in Kaplan-Meier method comparing 5-year PSA recurrence-free survival in patients with and without adjuvant therapy. When the patient clustered as non-adjuvant, only hormonal therapy and hormonal therapy with radiotherapy, a significant survival advantage was found in the hormonal therapy with radiotherapy group compared to the other two groups (p=0.043). Conclusion: No significant difference was found between two groups in terms of time until PSA recurrence during our follow-up. In subgroup analysis survival advantage was found in the hormonal therapy with radiotherapy group compared to non-adjuvant and only hormonal therapy groups. © This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.Item Oncological Outcomes of Patients with Non-Clear Cell Renal Cell Cancers: Subtypes of Unclassified and Translocation Renal Cell Cancers(Urology and Nephrology Research Centre, 2023) Gokalp F.; Celik S.; Sozen T.S.; Ozen A.H.; Aslan G.; Izol V.; Baltaci S.; Muezzinoglu T.; Akdogan B.; Suer E.; Tinay I.Purpose: We aimed to compare oncological outcomes in the two rare subtypes, unclassified renal cell cancer (unRCC) and translocation RCC (tRCC), vs clear cell RCC (ccRCC).Materials and Methods: Between 2004 and 2019, from Turkish Urooncology Society Database, we identified 2324 patients for histological subtypes including 80 unRCC (3.4%), 19 tRCC (0.8%) and 2225 ccRCC (95.8%).Results: The overall (15.8%) and cancer-specific mortalities (11.1%) were found to be higher in tRCC group and the recurrence free mortality (13.8%) was found to be higher in unRCC group. Larger pathological tumor size (p = 0.012) and advanced pathological T stage (p = 0.042) were independent predictive factors on overall mortality in patients with unRCC tumors.Conclusion: The oncological outcomes of the unRCC and tRCC are worse than ccRCC and pathological tumor size and pathological stage are predictive factors for mortality in the unRCC © 2023, Urology Journal.All Rights Reserved.Item Oncological Outcomes of Chromophobe Versus Clear Cell Renal Cell Carcinoma: Results from A Contemporary Turkish Patient Cohort(Urology and Nephrology Research Centre, 2024) Cetin T.; Celik S.; Sozen S.; Ozen H.; Akdogan B.; Aslan G.; Baltaci S.; Suer E.; Bayazit Y.; Izol V.; Muezzinoglu T.; Gokalp F.; Tinay I.Purpose: To compare the oncological outcomes of clear cell RCC (ccRCC), which is common in renal cell carcinomas (RCC), and chromophobic RCC (chRCC), which is less common, and to define the factors affecting survival in the Turkish patient population for both RCC subclassifications. Materials and Methods: Patients with a pathologically confirmed RCC diagnosis after radical or partial nephrectomy in the Turkish Urooncology Association (TUOA), Urological Cancers Database-Kidney (UroCaD-K), were retrospectively reviewed. Patients with ccRCC and chRCC were included in the study. Primary outcomes of this study are recurrence-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS) for each histological subtype. Results: Data from 5300 patients in the TUOA UroCaD-K are reviewed and a total of 2560 patients (2225 in the ccRCC group and 335 in the chRCC group) are included in the final analysis. In the comparison of the groups, tumor size was greater both radiologically and pathologically in chRCC (p=0.019 vs 0.002 respectively). Recurrence-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS) rates are worse in ccRCC subgroup. In the evaluation of risk factors; pathological stage, local invasion and Fuhrmann grade were found to be significant for recurrence in ccRCC. Age, body mass index and pathological stage were the risk factors affecting overall mortality (OM). Pathological tumor size was an independent risk factor for recurrence in chRCC, while age was analyzed as the only parameter affecting OM. Conclusion: chRCC oncological data and OS, CSS and RFS rates were found to be better than ccRCC in the Turkish patient population. © (2024), (Urology and Nephrology Research Centre). All Rights Reserved.Item Effect of Bacillus Calmette-Guérin Instillation Timing on Oncological Survivals After Transurethral Resection of Bladder Tumor(Elsevier Inc., 2025) Çetin T.; Bolat D.; Akgül M.; Yazıcı S.; Aslan G.; Akan S.; Baltacı S.; Müezzinoğlu T.; Bayazıt Y.Objective: To investigate whether the timing of bacillus Calmette-Guerin instillation (TTBCG), which plays a key role in treating non-muscle invasive bladder cancer (NMIBC), after transurethral resection of bladder tumor (TURBT) affects oncologic outcomes. Methods: Patient data obtained from the Urologic Cancer Database-Bladder (UroCaD-B) of Turkish Uro-oncology Association (TUOA) were evaluated. Data from 292 patients from 12 centers with primary T1HG treated with TURBT and maintenance BCG between 2003 and 2023 were retrospectively analyzed. The population was subdivided according to TTBCG, while recurrence-free survival (RFS) and progression-free survival (PFS) were estimated by log-rank tests and univariable and multivariable regression analyses. Results: A total of 292 patients were followed, and 86% (n = 251) of those included in the study were male. The median duration of TTBCG was 38.5 days (19-73). The median follow-up period was 38.4 months (21.5-72.1 months). During follow-up, recurrence was detected in 55 (18.5%) patients and progression was detected in 22 (7.5%) patients. In univariate Cox regression analysis, long TTBCG (> 27.5 days) was found to have a statistically significant effect on the risk of short RFS and PFS (P = .05). BCG-related side effects were not associated with TTBCG (P = .313). Kaplan-Meier analysis showed that there was a significant difference in RFS and PFS between the TTBCG groups (P = .04, P = .011, respectively). Conclusion: In this retrospective non-randomized study, we showed the negative effects of BCG delay on progression and recurrence in T1HG patients. Therefore, we think that BCG should be instilled within 4 weeks after surgery. © 2024 Elsevier Inc.